DCBO
Docebo Inc.
DCBO's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over DCBO overall, supported by stronger modeled upside and stronger valuation.
DCBO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
DCBO's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
DCBO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $32.48 | — |
| Cheap | 23x | $26.30 | -19% |
| Current | 28x | $32.48 | — |
| Fair | 75x | $86.97 | +168% |
| Expensive | 222x | $257 | +692% |
Historical ranges are pointers, not guarantees.
DCBO's PE is in its cheap range at 28x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over DCBO in the historical PE scenario, which offers more potential upside but is not a forecast.
DCBO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
DCBO has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
DCBO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.71 | +47% |
| Q2 2026 | $1.16 | +68% |
| Q1 2026 | $1.18 | +59% |
| Q4 2025 | $1.29 | +50% |
| Q3 2025 | $0.74 | +30% |
| Q2 2025 | $0.69 | +30% |
| Q1 2025 | $0.74 | +252% |
| Q4 2024 | $0.86 | +975% |
| Q3 2024 | $0.57 | +1040% |
DCBO's earnings per share have climbed steadily: $1.16 over the past year, up 68% from the year before, and higher year over year for nine quarters in a row.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over DCBO on earnings, with stronger typical year-over-year growth.
DCBO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $68.7M | +13% |
| Q1 2026 | $65.6M | +15% |
| Q4 2025 | $63M | +11% |
| Q3 2025 | $61.6M | +11% |
| Q2 2025 | $60.7M | +14% |
| Q1 2025 | $57.3M | +11% |
| Q4 2024 | $57M | +16% |
| Q3 2024 | $55.4M | +19% |
DCBO's revenue has grown year over year every quarter since late 2020: $69M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.1% | -1.3 points |
| Q1 2026 | -0.1% | -3 points |
| Q4 2025 | 15% | +1.2 points |
| Q3 2025 | 13% | +4.7 points |
| Q2 2025 | 8.4% | -0.2 points |
| Q1 2025 | 3% | -5.2 points |
| Q4 2024 | 14% | +12 points |
| Q3 2024 | 8.5% | +1.8 points |
DCBO's operating margin was 7.1% last quarter, down 1.3 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over DCBO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over DCBO on profitability, with a higher operating margin.
DCBO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.2M | -154% |
| Q1 2026 | $24M | +214% |
| Q4 2025 | $8.6M | -9.3% |
| Q3 2025 | $5.1M | +31% |
| Q2 2025 | $6M | -8% |
| Q1 2025 | $7.6M | -7% |
| Q4 2024 | $9.4M | +52% |
| Q3 2024 | $3.9M | -37% |
DCBO usually generates cash, though not every quarter: the latest was −$3M, but it generated $34M over the past year.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over DCBO on cash flow, with more consistent year-over-year improvement.
DCBO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.6% | -1.3M shares |
| 1 year | -11% | -3.4M shares |
| 3 years | -19% | -6.4M shares |
| 5 years | -18% | -6M shares |
| Available history | -5.8% | -1.7M shares |
DCBO has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $16.3M |
| Q1 2026 | $62.2M |
| Q4 2025 | $6,909 |
| Q3 2025 | $3.4M |
| Q2 2025 | $34.2M |
| Q4 2024 | $238,000 |
| Q3 2024 | $5.9M |
| Q2 2024 | $5.1M |
DCBO spent $82M buying back its own shares over the past year.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
DCBO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 2.0x | Healthy |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -2.5x | Net Cash |
| Q2 2025 | -2.8x | Net Cash |
| Q3 2024 | -4.2x | Net Cash |
| Q2 2024 | -4.7x | Net Cash |
DCBO's net debt is about 2.0 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over DCBO on leverage, with a lower net debt burden relative to earnings.
DCBO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.1 | Overbought |
| Stochastic | 85.1 | Overbought |
DCBO's weekly RSI is 72 (overbought) and its Stochastic is 85 (overbought).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
DCBO PE vs Technology Sector
| Metric | DCBO | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 28x | 0.3% above |
| PE % | 22 | 39 | 17 pts below |
DCBO is trading at 28x earnings, in line with the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over DCBO on valuation relative to its sector.
DCBO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.7 | 17% above |
| 20 week MA | $24.3 | 34% above |
| 50 week MA | $21.1 | 54% above |
| 100 week MA | $26.2 | 24% above |
| 200 week MA | $34.0 | 4.5% below |
DCBO has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
DCBO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.1 | $57.7 | +15% |
| 2021 | $57.7 | $68.1 | +18% |
| 2022 | $68.1 | $31.9 | -53% |
| 2023 | $31.9 | $48.4 | +51% |
| 2024 | $48.4 | $45.7 | -5.6% |
| 2025 | $45.7 | $22.2 | -51% |
| 2026 YTD | $22.2 | $32.5 | +46% |
DCBO has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.